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Background
Thrombocytosis is defined as an increase in the number
of circulating platelets than the normal value of between
150,000 and 250,000 platelets/uL. The limit beyond
which the state of platelets is usually marked in platelets
is defined as 400,000/uL.
Trombocytosis are divided into primary or autono-
mous, in the course of myeloproliferative disorders
(essential thrombocythemia, polycythemia vera, chronic
myelogenous leukemia) and secondary or reactive. The
primitive forms having a common origin as stem cells of
the bone marrow, and, although each has specific char-
acteristics, often the clinical picture overlaps, making it
difficult to secure a diagnosis between these four dis-
eases. Indeed, essentially thrombocythemia is always an
increase in platelets, but this can also occur in the other
three diseases, also in idiopathic thrombocythemia,
sooner or later, during the course of the disease, you
may have increased white blood cells and, very rarely,
even red blood cells. The duration of secondary throm-
bocytosis is variable and tied to the possibility of remov-
ing the underlying disease. The diagnosis is based on
the finding, the examination emocromocitimetrico, a
higher platelet rate than 400,000 items for UL with
volume, morphology and platelet function is normal,
and the search for possible pathological conditions that
led the platelets. Mieloroliferative diseases should be
excluded from the platelets, including essential throm-
bocythemia, which in addition to specific hematologic
abnormalities, have higher rates with strong anisomacro-
citosi platelet-platelet, and more frequent bleeding or
thrombotic. Several studies have shown that in most
patients with polycythemia vera and in about half of
those with essential thrombocythemia or idiopathic
myelofibrosis, it is a single nucleotide mutation that
activates JAK2.
Conclusions
JAK2 mutations appear to confer hypersensitivity to
hematopoietic growth factors and a selective advantage
for growth marrow precursors carrying the mutated
gene compared with normal or wild type precursors.
Recently it was discovered a point mutation dependent
kinase JAK2, which involves replacing a thymine with
guanine nucleotide sequence, resulting in the appear-
ance of a valine residue instead of phenylalanine in posi-
tion 617 of the amino acid sequence or JAK2617V> F.
This mutation appears to be myeloid-specific and can
be used for the differential diagnosis between primitive
myeloproliferative disorders and secondary forms of
poliglobulia or thrombocytosis.
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